Fresenius Medical Care AG & Co. KGaA Rating Reiterated by Sanford C. Bernstein (FME)

Fresenius Medical Care AG & Co. KGaA (ETR: FME)‘s stock had its “outperform” rating reiterated by equities research analysts at Sanford C. Bernstein in a research note issued to investors on Thursday. They currently have a $79.87 (€62) price target on the stock.

A number of other firms have also recently commented on FME. Analysts at AlphaValue reiterated an “add” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Thursday, March 7th. They now have a $78.83 price target on the stock. Separately, analysts at Piper Jaffray cut their price target on shares of Fresenius Medical Care AG & Co. KGaA from $37.00 to $34.00 in a research note to investors on Wednesday, February 27th. Finally, analysts at Goldman Sachs reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note to investors on Wednesday, February 27th. They now have a $68.83 price target on the stock.

Fresenius Medical Care AG & Co. KGaA (ETR: FME) traded up 0.46% on Thursday, hitting €51.83. Fresenius Medical Care AG & Co. KGaA has a 52-week low of €47.982 and a 52-week high of €60.24. The stock’s 50-day moving average is currently €56.72.

Fresenius Medical Care AG & Co KGaA is a Germany-based holding and kidney dialysis company, operating in the fields of dialysis products and dialysis services.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.